Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Invested Capital: 2017-2025

Historic Invested Capital for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $645.4 million.

  • Protagonist Therapeutics' Invested Capital rose 21.34% to $645.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.4 million, marking a year-over-year increase of 21.34%. This contributed to the annual value of $675.3 million for FY2024, which is 100.58% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Invested Capital of $645.4 million as of Q3 2025, which was down 3.38% from $668.0 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Invested Capital ranged from a high of $689.1 million in Q1 2025 and a low of $215.7 million during Q4 2022.
  • In the last 3 years, Protagonist Therapeutics' Invested Capital had a median value of $541.3 million in 2024 and averaged $496.4 million.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 266.27% in 2021, then decreased by 28.45% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Invested Capital (Quarterly) stood at $300.9 million in 2021, then fell by 28.33% to $215.7 million in 2022, then soared by 56.10% to $336.7 million in 2023, then skyrocketed by 100.58% to $675.3 million in 2024, then grew by 21.34% to $645.4 million in 2025.
  • Its last three reported values are $645.4 million in Q3 2025, $668.0 million for Q2 2025, and $689.1 million during Q1 2025.